AI Engines For more Details: Perplexity Kagi Labs You
Antiepileptic Properties: Pyrithyldione is primarily used to control seizures in individuals with epilepsy. It works by stabilizing neuronal membranes and decreasing the excitability of neurons, thereby reducing the occurrence and severity of seizures.
Control of Absence Seizures: Pyrithyldione is particularly effective in controlling absence seizures, which are characterized by brief periods of unconsciousness and staring spells. It helps prevent the sudden and brief loss of consciousness associated with this type of seizure.
Maintenance Therapy: Pyrithyldione is often used as a maintenance therapy in individuals with epilepsy to prevent the recurrence of seizures. It is typically administered orally in the form of tablets or capsules.
Side Effects: Like many antiepileptic drugs, pyrithyldione may cause side effects in some individuals. Common side effects may include dizziness, drowsiness, headache, nausea, vomiting, loss of appetite, and stomach upset. These side effects are usually mild and may improve over time as the body adjusts to the medication.
Blood Dyscrasias: Rare but serious side effects of pyrithyldione include blood dyscrasias such as agranulocytosis, leukopenia, and thrombocytopenia. Patients taking pyrithyldione should be monitored regularly for signs of blood disorders, including fever, sore throat, bruising, or unusual bleeding.
Liver Toxicity: Pyrithyldione has been associated with liver toxicity in some cases, including hepatotoxicity and hepatic failure. Patients should be monitored for signs of liver dysfunction, such as jaundice, abdominal pain, dark urine, and fatigue.
Teratogenicity: Pyrithyldione may pose risks to pregnant women and their unborn babies. It has been associated with an increased risk of congenital malformations and developmental delays when used during pregnancy. Pregnant women should only use pyrithyldione if the potential benefits outweigh the risks, and under the supervision of a healthcare provider.
Drug Interactions: Pyrithyldione may interact with other medications, including other antiepileptic drugs, leading to changes in blood levels and potentially increasing the risk of side effects or reducing the effectiveness of treatment. Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal supplements.
Discontinuation: As with many AEDs, pyrithyldione should not be discontinued abruptly, as this can increase the risk of breakthrough seizures. Instead, the dosage should be gradually tapered under the guidance of a healthcare professional.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.1 | 0.3 | -2 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Alzheimer's disease | 0.4 | -0.4 | |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
| Ankylosing spondylitis | 0.1 | 0.1 | |
| Anorexia Nervosa | 0.1 | -0.1 | |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 0.1 | -0.1 | |
| Atherosclerosis | 0.2 | -0.2 | |
| Atrial fibrillation | 0.4 | 0.4 | |
| Autism | 0.4 | 0.4 | 0 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| Bipolar Disorder | 0.4 | -0.4 | |
| Brain Trauma | 0.1 | -0.1 | |
| Carcinoma | 0.1 | 0.1 | |
| Celiac Disease | 0.1 | 0.1 | |
| Cerebral Palsy | 0.1 | 0.1 | 0 |
| Chronic Fatigue Syndrome | 0.6 | 1 | -0.67 |
| Chronic Kidney Disease | 0.4 | -0.4 | |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.4 | -1 |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.1 | 0 |
| Colorectal Cancer | 0.2 | 0.2 | |
| Constipation | 0.1 | -0.1 | |
| Coronary artery disease | 0.3 | -0.3 | |
| COVID-19 | 0.1 | 0.7 | -6 |
| Crohn's Disease | 0.4 | 0.4 | 0 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 1.2 | 1.9 | -0.58 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.2 | -0.2 | |
| Endometriosis | 0.4 | 0.4 | |
| Epilepsy | 0.1 | 0.1 | |
| Fibromyalgia | 0.1 | 0.6 | -5 |
| Functional constipation / chronic idiopathic constipation | 0.1 | 0.4 | -3 |
| gallstone disease (gsd) | 0.1 | -0.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
| Generalized anxiety disorder | 0.3 | -0.3 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.3 | -0.3 | |
| Graves' disease | 0.1 | -0.1 | |
| Halitosis | 0.1 | -0.1 | |
| Hashimoto's thyroiditis | 0.1 | 0.1 | |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.1 | 0.1 | |
| hypertension (High Blood Pressure | 0.1 | 0.4 | -3 |
| Hypothyroidism | 0.3 | -0.3 | |
| Inflammatory Bowel Disease | 0.2 | 0.5 | -1.5 |
| Insomnia | 0.1 | 0.1 | 0 |
| Intelligence | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.1 | 0.1 | 0 |
| Liver Cirrhosis | 0.4 | 0.4 | 0 |
| Long COVID | 0.7 | 0.4 | 0.75 |
| Low bone mineral density | 0.4 | -0.4 | |
| ME/CFS with IBS | 0.1 | 0.6 | -5 |
| ME/CFS without IBS | 0.2 | 0.2 | |
| Metabolic Syndrome | 0.4 | 0.4 | 0 |
| Mood Disorders | 1.6 | 1.9 | -0.19 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
| Multiple Sclerosis | 0.2 | 0.1 | 1 |
| Neuropathy (all types) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.3 | -2 |
| Obesity | 0.4 | 1.2 | -2 |
| obsessive-compulsive disorder | 0.1 | 0.3 | -2 |
| Osteoarthritis | 0.1 | 0.1 | |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.4 | 0.6 | -0.5 |
| Polycystic ovary syndrome | 0.1 | -0.1 | |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Psoriasis | 0.1 | 0.4 | -3 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.4 | 0.4 | 0 |
| Rosacea | 0.1 | -0.1 | |
| Schizophrenia | 0.3 | 0.4 | -0.33 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 0.1 | 0.1 | |
| Sleep Apnea | 0.3 | 0.4 | -0.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.1 | 0.4 | -3 |
| Systemic Lupus Erythematosus | 0.4 | 0.1 | 3 |
| Type 1 Diabetes | 0.3 | 0.1 | 2 |
| Type 2 Diabetes | 0.4 | 0.4 | 0 |
| Ulcerative colitis | 0.5 | 0.4 | 0.25 |
| Unhealthy Ageing | 0.4 | 0.4 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.